BioCentury
ARTICLE | Clinical News

Amicus gains on additional Phase II Pompe's disease data

January 5, 2013 12:35 AM UTC

Amicus Therapeutics Inc. (NASDAQ:FOLD) gained $0.28 (8%) to $3.58 on Friday after reporting additional data from the fourth and final cohort of the Phase II Study 010 trial of AT2220 for Pompe's disease. Additional data from seven patients in the cohort showed single doses of 600 mg AT2220 plus enzyme replacement therapy (ERT) increased recombinant human acid alpha glucosidase (GAA) activity by 110% compared to ERT alone. Amicus plans to begin a repeat-dose clinical trial with duvoglustat in 3Q13, but declined to disclose a phase for the trial. AT2220 is a chaperone that binds to GAA. ...